<SEC-DOCUMENT>0000950170-25-073522.txt : 20250516
<SEC-HEADER>0000950170-25-073522.hdr.sgml : 20250516
<ACCEPTANCE-DATETIME>20250516160523
ACCESSION NUMBER:		0000950170-25-073522
CONFORMED SUBMISSION TYPE:	4
PUBLIC DOCUMENT COUNT:		1
CONFORMED PERIOD OF REPORT:	20250515
FILED AS OF DATE:		20250516
DATE AS OF CHANGE:		20250516

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Finn Jonathan
		CENTRAL INDEX KEY:			0001981595
		ORGANIZATION NAME:           	

	FILING VALUES:
		FORM TYPE:		4
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-35610
		FILM NUMBER:		25959052

	MAIL ADDRESS:	
		STREET 1:		C/O VANTAGE CONSULTING GROUP, INC.
		STREET 2:		3500 PACIFIC AVENUE
		CITY:			VIRGINIA BEACH
		STATE:			VA
		ZIP:			23451

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			ATOSSA THERAPEUTICS, INC.
		CENTRAL INDEX KEY:			0001488039
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		ORGANIZATION NAME:           	03 Life Sciences
		EIN:				264753208
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		10202 5TH AVENUE NE
		STREET 2:		SUITE 200
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98125
		BUSINESS PHONE:		206.588.0256

	MAIL ADDRESS:	
		STREET 1:		10202 5TH AVENUE NE
		STREET 2:		SUITE 200
		CITY:			SEATTLE
		STATE:			WA
		ZIP:			98125

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	ATOSSA GENETICS INC
		DATE OF NAME CHANGE:	20100325
</SEC-HEADER>
<DOCUMENT>
<TYPE>4
<SEQUENCE>1
<FILENAME>ownership.xml
<DESCRIPTION>4
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0508</schemaVersion>

    <documentType>4</documentType>

    <periodOfReport>2025-05-15</periodOfReport>

    <issuer>
        <issuerCik>0001488039</issuerCik>
        <issuerName>ATOSSA THERAPEUTICS, INC.</issuerName>
        <issuerTradingSymbol>ATOS</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001981595</rptOwnerCik>
            <rptOwnerName>Finn Jonathan</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>C/O ATOSSA THERAPEUTICS, INC.,</rptOwnerStreet1>
            <rptOwnerStreet2>10202 5TH AVE NE, SUITE 200</rptOwnerStreet2>
            <rptOwnerCity>SEATTLE</rptOwnerCity>
            <rptOwnerState>WA</rptOwnerState>
            <rptOwnerZipCode>98125</rptOwnerZipCode>
            <rptOwnerStateDescription></rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>true</isDirector>
            <isOfficer>false</isOfficer>
            <isTenPercentOwner>false</isTenPercentOwner>
            <isOther>false</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <aff10b5One>false</aff10b5One>

    <derivativeTable>
        <derivativeTransaction>
            <securityTitle>
                <value>Stock Option (right to buy)</value>
            </securityTitle>
            <conversionOrExercisePrice>
                <value>0.99</value>
            </conversionOrExercisePrice>
            <transactionDate>
                <value>2025-05-15</value>
            </transactionDate>
            <transactionCoding>
                <transactionFormType>4</transactionFormType>
                <transactionCode>A</transactionCode>
                <equitySwapInvolved>false</equitySwapInvolved>
            </transactionCoding>
            <transactionAmounts>
                <transactionShares>
                    <value>125000</value>
                </transactionShares>
                <transactionPricePerShare>
                    <value>0</value>
                </transactionPricePerShare>
                <transactionAcquiredDisposedCode>
                    <value>A</value>
                </transactionAcquiredDisposedCode>
            </transactionAmounts>
            <exerciseDate>
                <footnoteId id="F1"/>
            </exerciseDate>
            <expirationDate>
                <value>2035-05-15</value>
            </expirationDate>
            <underlyingSecurity>
                <underlyingSecurityTitle>
                    <value>Common Stock</value>
                </underlyingSecurityTitle>
                <underlyingSecurityShares>
                    <value>125000</value>
                </underlyingSecurityShares>
            </underlyingSecurity>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>125000</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </derivativeTransaction>
    </derivativeTable>

    <footnotes>
        <footnote id="F1">The options shall vest on a quarterly basis over 12 months following May 15, 2025, subject to the Reporting Person's continued service through each applicable vesting date. The options were issued on May 15, 2025 with an exercise price of $0.99, representing the closing stock price on May 15, 2025.</footnote>
    </footnotes>

    <ownerSignature>
        <signatureName>/s/ Jonathan Finn</signatureName>
        <signatureDate>2025-05-16</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
